BANTAM PHARMACEUTICAL TO PRESENT AT BIOTECH SHOWCASE™ 2023

• Developing Novel Selective Modulators of Mitochondrial Dynamics (SeMMiDs)
• A differentiated therapeutic approach for treating aggressive cancer

RALEIGH, N.C., Jan. 9, 2023 /PRNewswire/ -- Bantam Pharmaceutical, LLC announces that it is presenting at the Biotech Showcase taking place in San Francisco, the 9^th-11^th of January and virtually, on demand the 18^th and 19^th of January.

Bantam Pharmaceutical is developing first-in-class therapeutics that leverage the "cellular power plants," known as mitochondria, to destroy cancer cells.

Bantam has a novel, oral therapeutic, BTM-3566, with an FDA-cleared IND featuring a phase 1 study in B cell lymphomas. BTM-3566 targets mitochondrial homeostasis, with exceptional single-agent activity in hematological malignancies, including complete responses in diffuse large B-Cell lymphoma (DLBCL) in vivo models. These models were derived from patient tumors with multiple genomic alterations that underlie the high death rates in these difficult-to-treat lymphomas.

The presentation by Bantam Pharmaceutical President and CEO Michael Stocum will cover BTM-3566 novel anti-cancer mechanism and the company's potential to bring novel cancer agents closer to patients in need.  Bantam features a leadership team of industry veterans, with most having over two decades of experience across several therapeutic areas in pharmaceuticals, biologics, and molecular diagnostics.

Presenter: Michael Stocum, President & CEO, Bantam Pharmaceutical

Date: Tuesday, January 10, 2023

Time: 2:45pm PST

Track: Franciscan B (Ballroom Level)

Michael Stocum, CEO of Bantam Pharmaceutical, commented: "It's a transformative time for Bantam and I'm excited to share the latest updates and data during the Biotech Showcase. Patients with relapsed and refractory Lymphoma need additional treatment options. Bantam is ready to address this clear unmet medical need."

Bantam Pharmaceutical is a drug discovery and development company channeling the power of mitochondrial dynamics to address unmet needs in oncology. Using its unique expertise in mitochondrial cellular biology, Bantam is developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors. Bantam has IND clearance from the US Food and Drug Administration (FDA) for its lead candidate, BTM-3566, in B-cell malignancies.
Learn more at https://bantampharma.com/.

Company Contact:

Meghan Reynolds, Chief of Staff
646.598.4823
info@bantampharma.com
www.bantampharma.com

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 15th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

SOURCE Bantam Pharmaceutical, LLC